SynthesisCancer research2025
The Medulloblastoma Meta-Analysis Portal Enables Integrative Exploration of Clinical and Genomic Data from Patients.
Synthesis in Cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Developmental determinants of male bias in medulloblastoma.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Medulloblastoma is a prevalent, highly heterogeneous malignant pediatric brain cancer. In this study, we developed the Medulloblastoma Meta-Analysis portal, a web-based data analysis and visualization platform that consolidates clinical, molecular, and survival data of 898 patients from three major clinical trials (ACNS0331, ACNS0332, and SJMB03). The portal integrated clinical data with genomic mutations and DNA methylomes, enabling in-depth analyses of tumor subgroups and survival outcomes. Dynamic exploration and custom stratification of these data were made possible by the portal's user-friendly visualization tools powered by the ProteinPaint framework, allowing users to select from a wide range of variables or customize their own. The Cox regression analysis tool in the portal demonstrated utility in examining the prognostic impact of variables across a heterogeneous dataset. Additionally, an in-depth exploration of medulloblastomas that harbor KBTBD4 mutations and their corresponding methylomes generated leads that could help improve molecular classification. These use cases underscore the portal's utility in enhancing risk stratification, informing tailored therapeutic strategies, and revealing the complexities of molecular heterogeneity in patients with medulloblastoma. The portal, along with links to the tutorials and live figures, is freely available at https://viz.stjude.cloud/st-jude-childrens-research-hospital/visualization/medulloblastoma-integrative-analysis-portal~2882. SIGNIFICANCE: The MB-meta portal facilitates risk stratification of patients using molecular, genomic, clinical, and demographic data, representing a significant step in neuro-oncology data sharing by offering an intuitive web-based platform for complex analyses.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.